![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAL |
Gene summary for MAL |
![]() |
Gene information | Species | Human | Gene symbol | MAL | Gene ID | 4118 |
Gene name | mal, T cell differentiation protein | |
Gene Alias | MVP17 | |
Cytomap | 2q11.1 | |
Gene Type | protein-coding | GO ID | GO:0001766 | UniProtAcc | A0A024RE19 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4118 | MAL | P23T-E | Human | Esophagus | ESCC | 4.29e-11 | 8.19e-01 | 0.108 |
4118 | MAL | P128T-E | Human | Esophagus | ESCC | 3.99e-07 | 9.11e-01 | 0.1241 |
4118 | MAL | S014 | Human | Liver | HCC | 1.15e-08 | 7.37e-01 | 0.2254 |
4118 | MAL | S015 | Human | Liver | HCC | 2.71e-07 | 8.24e-01 | 0.2375 |
4118 | MAL | S016 | Human | Liver | HCC | 7.18e-17 | 1.19e+00 | 0.2243 |
4118 | MAL | C43 | Human | Oral cavity | OSCC | 7.87e-03 | -1.70e-01 | 0.1704 |
4118 | MAL | LN22 | Human | Oral cavity | OSCC | 5.83e-06 | 2.19e+00 | 0.1733 |
4118 | MAL | SYSMH4 | Human | Oral cavity | OSCC | 4.35e-08 | 1.01e-01 | 0.1226 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004328125 | Oral cavity | EOLP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 60/2218 | 209/18723 | 3.09e-11 | 4.30e-09 | 60 |
GO:005254825 | Oral cavity | EOLP | regulation of endopeptidase activity | 98/2218 | 432/18723 | 1.12e-10 | 1.29e-08 | 98 |
GO:005116824 | Oral cavity | EOLP | nuclear export | 47/2218 | 154/18723 | 4.45e-10 | 3.76e-08 | 47 |
GO:000715917 | Oral cavity | EOLP | leukocyte cell-cell adhesion | 86/2218 | 371/18723 | 5.01e-10 | 4.11e-08 | 86 |
GO:190370624 | Oral cavity | EOLP | regulation of hemopoiesis | 85/2218 | 367/18723 | 6.61e-10 | 5.06e-08 | 85 |
GO:004578526 | Oral cavity | EOLP | positive regulation of cell adhesion | 95/2218 | 437/18723 | 2.30e-09 | 1.47e-07 | 95 |
GO:001095224 | Oral cavity | EOLP | positive regulation of peptidase activity | 53/2218 | 197/18723 | 5.39e-09 | 2.91e-07 | 53 |
GO:005086316 | Oral cavity | EOLP | regulation of T cell activation | 76/2218 | 329/18723 | 5.96e-09 | 3.11e-07 | 76 |
GO:190303716 | Oral cavity | EOLP | regulation of leukocyte cell-cell adhesion | 77/2218 | 336/18723 | 6.89e-09 | 3.53e-07 | 77 |
GO:002240719 | Oral cavity | EOLP | regulation of cell-cell adhesion | 93/2218 | 448/18723 | 3.65e-08 | 1.41e-06 | 93 |
GO:190313114 | Oral cavity | EOLP | mononuclear cell differentiation | 88/2218 | 426/18723 | 1.07e-07 | 3.61e-06 | 88 |
GO:001095024 | Oral cavity | EOLP | positive regulation of endopeptidase activity | 46/2218 | 179/18723 | 2.35e-07 | 7.37e-06 | 46 |
GO:004312223 | Oral cavity | EOLP | regulation of I-kappaB kinase/NF-kappaB signaling | 58/2218 | 249/18723 | 2.72e-07 | 8.22e-06 | 58 |
GO:00466314 | Oral cavity | EOLP | alpha-beta T cell activation | 41/2218 | 156/18723 | 5.51e-07 | 1.47e-05 | 41 |
GO:190210514 | Oral cavity | EOLP | regulation of leukocyte differentiation | 62/2218 | 279/18723 | 6.18e-07 | 1.60e-05 | 62 |
GO:00466344 | Oral cavity | EOLP | regulation of alpha-beta T cell activation | 31/2218 | 104/18723 | 7.06e-07 | 1.81e-05 | 31 |
GO:000724924 | Oral cavity | EOLP | I-kappaB kinase/NF-kappaB signaling | 62/2218 | 281/18723 | 8.00e-07 | 2.02e-05 | 62 |
GO:200105623 | Oral cavity | EOLP | positive regulation of cysteine-type endopeptidase activity | 39/2218 | 148/18723 | 9.60e-07 | 2.38e-05 | 39 |
GO:003009812 | Oral cavity | EOLP | lymphocyte differentiation | 76/2218 | 374/18723 | 1.50e-06 | 3.55e-05 | 76 |
GO:000166624 | Oral cavity | EOLP | response to hypoxia | 65/2218 | 307/18723 | 2.00e-06 | 4.55e-05 | 65 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAL | SNV | Missense_Mutation | c.88N>C | p.Glu30Gln | p.E30Q | P21145 | protein_coding | deleterious(0.01) | possibly_damaging(0.881) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MAL | SNV | Missense_Mutation | rs745729561 | c.139C>T | p.Pro47Ser | p.P47S | P21145 | protein_coding | tolerated(0.1) | probably_damaging(0.988) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | rs775300945 | c.428N>T | p.Ala143Val | p.A143V | P21145 | protein_coding | tolerated(0.05) | benign(0.426) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAL | SNV | Missense_Mutation | novel | c.254N>C | p.Val85Ala | p.V85A | P21145 | protein_coding | tolerated(0.47) | benign(0.243) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MAL | SNV | Missense_Mutation | c.359G>T | p.Arg120Met | p.R120M | P21145 | protein_coding | deleterious(0.03) | benign(0.369) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAL | SNV | Missense_Mutation | c.127T>A | p.Ser43Thr | p.S43T | P21145 | protein_coding | deleterious(0.02) | possibly_damaging(0.744) | TCGA-CM-6679-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
MAL | SNV | Missense_Mutation | rs749751444 | c.335N>T | p.Thr112Met | p.T112M | P21145 | protein_coding | tolerated(0.22) | benign(0.022) | TCGA-D5-6924-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | novel | c.145N>G | p.Pro49Ala | p.P49A | P21145 | protein_coding | tolerated(0.16) | benign(0.039) | TCGA-DM-A28F-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | rs775300945 | c.428N>T | p.Ala143Val | p.A143V | P21145 | protein_coding | tolerated(0.05) | benign(0.426) | TCGA-AX-A0IZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAL | SNV | Missense_Mutation | novel | c.89A>G | p.Glu30Gly | p.E30G | P21145 | protein_coding | deleterious(0) | probably_damaging(0.913) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |